Monday, November 2, 2009

Byetta (exenatide) - Altered kidney function, including acute renal failure/renal insufficiency, in patients on Byetta

Nov. 2, 2009--FDA notified healthcare professionals of revisions to the prescribing information for Byetta (exenatide) to include information on post-marketing reports of altered kidney function, including acute renal failure and insufficiency. Byetta, an incretin-mimetic, is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

The details can be read here.

No comments: